Effect of a Topical Spray on Itch Relief in Moderate-to-severe Childhood Eczema
Status:
Completed
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
Pruritus is defined as an unpleasant sensation of the skin that provoke the desire to scratch
or rub. Its presence is an essential diagnostic feature. According to some European studies,
91% of patients with Atopic Dermatitis report suffering from pruritus at least once daily.
And 58.1% of them experience chronic pruritus, leading to great deterioration in quality of
life. Various internal and external factors may trigger pruritus. Mediators secretion such as
keratinocyte-derived Thymic Stromal Lymphopoietin (TSLP) and Nerve Growth Factor (NGF) could
activate nerve fibres which will eventually transmit signals to the brain causing the
sensation of itching.
Although being one of the major annoying symptoms faced by patients with Atopic Dermatitis,
effective anti-itching treatments are not available. There is no consistent evidence that
topical antihistamines can relief itch.
Recently, a new spray named Atoderm 'SOS' is developed. The skin relief technology (by ambora
extract and Epigallocatechin gallate (EGCG), associated to enoxolone) claimed to inhibit the
release TSLP and NGF which eventually could reduce nerve signals to the brain for itchy
feelings. Therefore, our group would like to test the efficacy of this proprietary anti-itch
product with our paediatric patients using a wait-list approach as a control. It is aimed to
demonstrate that the using the Atoderm 'SOS' spray topically whenever necessary can reduce
the unpleasant itchy Atopic Dermatitis's symptom, improve quality of life, as well as to
reduce the need for topical treatment.